611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Metabolomic Profiles Differ With Macular DegenerationExtended Thromboprophylaxis Safe, Effective After Liver SurgeryExercise May Stem Kidney Damage in Lupus PatientsMinorities Exposed to Dirtier Air, U.S. Study FindsDoctors Eye the Danger From 'Nerf' GunsHealth Tip: Preventing Food Allergies While Dining OutIt's a Food Allergy! Where's the School Nurse?Lower Mortality Risk Seen With Statin Use in Older MenSleep Quality, Duration Linked to CKD ProgressionSelena Gomez's Kidney Transplant Puts Lupus Center StageVision Problems Common in Babies Infected With ZikaSmoking, Poor Diet Lead Global Death CausesWhich Single Behavior Best Prevents High Blood Pressure?Traces of Tattoo May Reach the Lymph NodesVitamin D Deficiency Tied to Neuropathic Pain'Upside' to Diabetes Really Isn'tSemen Harbors Wide Range of VirusesHeath Tip: Contact Lenses Aren't Risk-FreeDiabetes Threatens Kidneys, Vision of Millions of AmericansNew Guideline Aims to Help Doctors Diagnose Head, Neck Masses'Microbiomes' May Hold Key to Kids' Ear InfectionsWarfarin, Rivaroxaban Similarly Safe, EffectiveHealth Tip: Leading Causes of Food PoisoningER Visits for These 3 Health Woes Don't Have to Happen'Modest at Best' Discriminatory Ability for CBC Test in InfantsDo E-Cigarettes Damage Blood Vessels?'Healthy' Obese Still Face Higher Heart RisksTake a Stand Against Sitting Too MuchGreater Height Tied to Higher Risk of Venous ThromboembolismZika Virus Preferentially Targets Glioblastoma Stem CellsBiomarkers Can Predict Rapid Drop in Renal Function in T2DMPeople Picking Up Infection From Pet Store Puppies' Poop: CDCHeath Tip: Getting Rid of Head LiceThe Health Risks of Long Work WeeksLupus Hits Certain Groups HarderSocioeconomic Conditions Affect Metabolic Syndrome RiskAirway Mucin Concentrations May Help Predict Chronic BronchitisCenter Surgical Volume Linked to LVAD Patient OutcomesGuinea Pigs Harbor a Hidden Health HazardHealth Tip: Antibiotic-Resistant BacteriaFor City Kids With Asthma, Nearby Green Space Is KeyThe Best Way to Diagnose a Food AllergyBudget Cuts Threaten Research on Antimicrobial ResistanceIntensive BP Control Associated With Increased CKD RiskNo Easy Road Back for Ebola SurvivorsReduced Asthma Exacerbations Seen With TezepelumabEarly Respiratory Infections Tied to Celiac in High-Risk ChildrenStatins Help Healthy People Lower Their 'Bad' CholesterolRemember This: A Healthy Body Keeps the Mind Sharp, TooAcid Reflux? Try Going Vegetarian
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Biomarkers Can Predict Rapid Drop in Renal Function in T2DM


HealthDay News
Updated: Sep 11th 2017

new article illustration

MONDAY, Sept. 11, 2017 (HealthDay News) -- Plasma biomarkers that may improve the prediction of rapid decline in renal function in type 2 diabetes have been identified, according to a study published online Aug. 29 in Diabetes Care.

Kirsten E. Peters, Ph.D., from the University of Western Australia, and colleagues measured baseline biomarkers in 345 community-based patients from the Fremantle Diabetes Study Phase II. Clinical predictors of rapid estimated glomerular filtration rate (eGFR) decline trajectory defined by semiparametric group-based modeling were determined.

The researchers found in an eGFR trajectory analysis that 10.1 percent of participants were rapid decliners, with a mean decrease of 2.9 mL/min/1.73 m²/year. Plasma apolipoprotein (apo) A-IV (apoA4), CD5 antigen-like (CD5L), and complement C1q subcomponent subunit B (C1QB) independently predicted rapid decline after adjustment for clinical predictors (odds ratios, 2.4, 0.52, and 2.41, respectively), and they improved model performance and fit, discrimination (area under the curve, 0.75 to 0.82), and reclassification (net reclassification index, 0.76; integrated discrimination improvement, 6.3 percent). Together with insulin-like growth factor binding protein 3 (IBP3), these biomarkers contributed to improved model performance in predicting other indices of rapid eGFR decline.

"The current study has identified novel plasma biomarkers (apoA4, CD5L, C1QB, and IBP3) that may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in type 2 diabetes," the authors write.

Several authors are employees of Proteomics International. Proteomics International and the University of Western Australia are owners of a patent relating to the biomarkers described in the study, and several authors are named inventors on the patent.

Abstract
Full Text (subscription or payment may be required)